Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. - Hamlin PA; Flinn IW; Wagner-Johnston N; Burger JA; Coffey GP; Conley PB; Michelson G; Leeds JM; Der K; Kim Y; Sabalvaro-Torres A; Birrell M; et al. (American journal of hematology, 2019)